Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel

Sponsor: Ipsen Bioscience

Protocol D-US-60010-001: An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas